Citalopram versus other anti-depressive agents for depression

Cochrane Database of Systematic Reviews

Volumn , Issue 2, 2007, Pages

  Imperadore, G ^b   Cipriani, Andrea ^a   Signoretti, A ^b   Furukawa, T A ^b   Watanabe, N ^b   Churchill, R ^b   McGuire, H F ^b   Barbui, C ^b  

^a UNIVERSITY OF VERONA   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; CITALOPRAM; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; HYPERICUM EXTRACT; MILNACIPRAN; MIRTAZAPINE; PAROXETINE; REBOXETINE; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

AGITATION; ANXIETY; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DROWSINESS; DRUG EFFICACY; DRUG TOLERABILITY; HAMILTON SCALE; HUMAN; HYPOTENSION; INSOMNIA; MAJOR DEPRESSION; MICTURITION DISORDER; MONOTHERAPY; NAUSEA; QUALITY OF LIFE; REMISSION; REVIEW; SIDE EFFECT; SOCIAL ADAPTATION; SOCIAL STATUS; SOMNOLENCE; SUICIDE; SUICIDE ATTEMPT; TREATMENT OUTCOME; VOMITING; XEROSTOMIA;

EID: 44949118585     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD006534     Document Type: Review

References (50)

1. Als-Nielsen 2003 Als-Nielsen B, Chen W, Gluud C, Kjaergard LL. Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events?. JAMA 2003;290(7):921-8.
2. Altman 1996 Altman DG, Bland JM. Detecting skewness from summary information. BMJ 1996;313(7066):1200.
3. Anderson 2000 Anderson IM, Nutt DJ, Deakin JF. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines. Journal of Psychopharmacology 2000;14(1):3-20.
4. APA 1980 American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-III). 3rd Edition. Washington, DC: American Psychiatric Association, 1980.
5. APA 1987 American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-III-R). 3rd Edition. Washington, DC: American Psychiatric Association, 1987.
6. APA 1994 American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). 4th Edition. Washington, DC: American Psychiatric Association, 1994.
7. APA 2000 American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder (revision). American Journal of Psychiatry 2000;157(4 Suppl):1-45.
8. Barbui 2000 Barbui C, Hotopf M, Freemantle N, Boynton J, Churchill R, Eccles MP, et al. Selective serotonin reuptake inhibitors versus tricyclic and heterocyclic antidepressants: comparison of drug adherence. Cochrane Database of Systematic Reviews 2000, Issue 1.
9. Barbui 2004 Barbui C, Cipriani A, Brambilla P, Hotopf M. "Wish bias" in antidepressant drug trials?. Journal of Clinical Psychopharmacology 2004;24(2):126-30.
10. Bhandari 2004 Bhandari M, Busse JW, Jackowski D, Montori VM, Schunemann H, Sprague S, et al. Association between industry funding and statistically significant pro-industry findings in medical and surgical randomized trials. CMAJ 2004;170(4):477-80.
11. Bollini 1999 Bollini P, Pampallona S, Tibaldi G, Kupelnick B, Munizza C. Effectiveness of antidepressants. Meta-analysis of dose-effect relationships in randomised clinical trials. British Journal of Psychiatry 1999;174:297-303.
12. Buchkowsky 2004 Buchkowsky SS, Jewesson PJ. Industry sponsorship and authorship of clinical trials over 20 years. Annals of Pharmacotherapy 2004;38(4):579-85.
13. Cipriani 2005 Cipriani A, Brambilla P, Furukawa T, Geddes J, Gregis M, Hotopf M, et al. Fluoxetine versus other types of pharmacotherapy for depression. Cochrane Database of Systematic Reviews 2005, Issue 4.Art. No.: CD004185. DOI:10.1002/14651858.CD004185.pub2.
14. Cipriani 2006 Cipriani A, Barbui C, Brambilla P, Furukawa TA, Hotopf M, Geddes JR. Are All Antidepressants Really the Same? The Case of Fluoxetine: A Systematic Review. J Clin Psychiatry 2006;67(6):850- 864.
15. Ciuna 2004 Ciuna A, Andretta M, Corbari L, Levi D, Mirandola M, Sorio A, et al. Are we going to increase the use of antidepressants up to that of benzodiazepines?. European Journal of Clinical Pharmacology 2004;60(9):629-34.
16. Ellis 2004 Ellis P. Australian and New Zealand clinical practice guidelines for the treatment of depression. Australian and New Zealand Journal of Psychiatry 2004;38(6):389-407.
17. Furukawa 2002a Furukawa TA, Guyatt GH, Griffith LE. Can we individualize the 'number needed to treat'? An empirical study of summary effect measures in meta-analyses. International Journal of Epidemiology 2002;31(1):72-6.
18. Furukawa 2002b Furukawa TA, McGuire H, Barbui C. Meta-analysis of effects and side effects of low dosage tricyclic antidepressants in depression: systematic review. BMJ 2002;325(7371):991-5.
19. Furukawa 2005 Furukawa TA, Cipriani A, Barbui C, Brambilla P, Watanabe N. Imputing response rates from means and standard deviations in meta-analysis. International Clinical Psychopharmacology 2005;20(1):49-52.
20. Furukawa 2006 Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N. Imputing missing standard deviations in meta-analyses can provide accurate results. Journal of Clinical Epidemiology 2006;59(1):7- 10.
21. Geddes 2000 Geddes JR, Freemantle N, Mason J, Eccles MP, Boynton J. SSRIs versus other antidepressants for depressive disorder. Cochrane Database of Systematic Reviews 2000, Issue 2.
22. Guaiana 2003 Guaiana G, Barbui C, Hotopf M. Amitriptyline versus other types of pharmacotherapy for depression. Cochrane Database of Systematic Reviews 2003, Issue 2.
23. Guaiana 2005 Guaiana G, Andretta M, Corbari L, Mirandola M, Sorio A, D'Avanzo B, et al. Antidepressant drug consumption and public health indicators in Italy, 1955 to 2000. Journal of Clinical Psychiatry 2005;66(6):750-5.
24. Guy 1970 Guy W, Bonato RR. Manual for the ECDEU Assessment Battery.2. Chevy Chase, MD: National Institute of Mental Health, 1970.
25. Hamilton 1960 Hamilton M. A rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry 1960;23:56-62.
26. Hansen 2005 Hansen RA, Gartlehner G, Lohr KN, Gaynes BN, Carey TS. Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder. Annals of Internal Medicine 2005;143(6):415-26.
27. Higgins 2003 Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557- 60.
28. Higgins 2005 Higgins JP, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions. Chichester: John Wiley & Sons, Ltd, 2006.
29. Khan 2003 Khan A, Khan SR, Walens G, Kolts R, Giller EL. Frequency of positive studies among fixed and flexible dose antidepressant clinical trials: an analysis of the food and drug administration summary basis of approval reports. Neuropsychopharmacology 2003;28(3):552-7.
30. Lexchin 2003 Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ 2003;326(7400):1167-70.
31. Luborsky 1962 Luborsky L. Clinician's judgments of mental health. Archives of General Psychiatry 1962;7:407-17.
32. Malvini 2006 Malvini L, Cipriani A, Furukawa TA, McGuire H, Churchill R, Barbui C for the MANGA Study. Sertraline versus other antidepressive agents for depression. (Protocol). Cochrane Database of Systematic Reviews 2006, Issue 3.
33. Montgomery 1979 Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. British Journal of Psychiatry 1979;134:382-9.
34. Montgomery 2004 Montgomery JH, Byerly M, Carmody T, Li B, Miller DR, Varghese F, et al. An analysis of the effect of funding source in randomized clinical trials of second generation antipsychotics for the treatment of schizophrenia. Controlled Clinical Trials 2004;25(6):598-612.
35. NICE 2004 National Institute for Clinical Excellence. Depression: management of depression in primary and secondary care. London: National Institute for Clinical Excellence, 2004.
36. Omori 2006 Omori I, Watanabe N, Cipriani A, Barbui C, McGuire H, Churchill R and Furukawa TA for the MANGA Study. Fluvoxamine versus other anti-depressive agents for depression. (Protocol). Cochrane Database of Systematic Reviews Co2006, Issue 3.
37. Oxman 1992 Oxman AD, Guyatt GH. A consumer's guide to subgroup analyses. Annals of Internal Medicine 1992;116(1):78-84.
38. Perlis 2005 Perlis RH, Perlis CS, Wu Y, Hwang C, Joseph M, Nierenberg AA. Industry sponsorship and financial conflict of interest in the reporting of clinical trials in psychiatry. American Journal of Psychiatry 2005;162(10):1957-60.
39. Procyshyn 2004 Procyshyn RM, Chau A, Fortin P, Jenkins W. Prevalence and outcomes of pharmaceutical industry-sponsored clinical trials involving clozapine, risperidone, or olanzapine. Canadian Journal of Psychiatry - Revue Canadienne De Psychiatrie 2004;49(9):601-6.
40. Puech 1997 Puech A, Montgomery SA, Prost JF, Solles A, Briley M. Milnacipran, a new serotonin and noradrenaline reuptake inhibitor: an overview of its antidepressant activity and clinical tolerability. International Clinical Psychopharmacology 1997;12(2):99-108.
41. Smith 2002 Smith D, Dempster C, Glanville J, Freemantle N, Anderson I. Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis. British Journal of Psychiatry 2002;180:396-404.
42. Trivedi 2006 Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, Norquist G, Howland RH, Lebowitz B, McGrath PJ, Shores-Wilson K, Biggs MM, Balasubramani GK, Fava M, STAR*D Study Team. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006;163(1):28-40.
43. Ware 1993 Ware JE, Snow KK, Kosinski M, & Gandek B. SF-36 Health Survey Manual and Interpretation Guide. Boston, MA: New England Medical Centre, 1993.
44. Watanabe 2006 WHO 1978 WHO 1978. The Ninth Revision of the International Classification of Diseases and Related Health Problems (ICD-9). Geneva: World Health Organization, 1978.
45. WHO 1992 World Health Organization. The Tenth Revision of the International Classification of Diseases and Related Health Problems (ICD-10). Geneva: World Health Organization, 1992.
46. WHO 2006 World Health Organization. WHO Collaborative Centre for Drug Statistics Methodology. http://www.whocc.no/atcddd/.
47. WHOQOL Group 1998 WHOQOL Group. The World Health Organization quality of life assessment (WHOQOL): Development and general psychometric properties. Social Science and Medicine 1998;46(12):1569-85.
48. Williams 2000 Williams JW Jr, Mulrow CD, Chiquette E, Noel PH, Aguilar C, Cornell J. A systematic review of newer pharmacotherapies for depression in adults: evidence report summary. Annals of Internal Medicine 2000;132(9):743-56.
49. Wing 1994 Wing J. Measuring mental health outcomes: a perspective from the Royal College of Psychiatrists. Outcomes into Clinical Practice. London: BMJ Publishing, 1994.
50. Zimmerman 2004 Zimmerman M, Posternak MA, Chelminski I. Derivation of a definition of remission on the Montgomery-Asberg depression rating scale corresponding to the definition of remission on the Hamilton rating scale for depression. J Psychiatr Res 2004;38(6):577-82.